1stOncology™: Cancer Intelligence Service – Page 11578 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Shanghai ImmuneOnco Raises $6.4 Million for Immunotherapies

On February 21, 2020 Shanghai’s ImmuneOnco Biopharma reported that it raised $6.4 million in a Pre-B round to support its pre-clinical portfolio of immunotherapy cancer candidates (Press release, ImmuneOnco Biopharma, FEB 21, 2020, View Source [SID1234554623]). Founded in 2015, the company is developing bi-specific antibodies, novel recombinant proteins, target-specific natural killer (NK) cells, a target-activated NK (TANK) cell therapy, a CAR-T cell therapy, and mAbs that target immune regulation pathways. Tian Wenzhi, chairman and general manager, said the capital would support clinical studies of two ImmuneOnco candidates, IMM01 and IMM0306.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Centene To Present At Barclays Global Healthcare Conference

On February 21, 2020 Centene Corporation (NYSE: CNC) reported it will present at the Barclays Global Healthcare Conference, to be held at the Loews Miami Beach Hotel, March 10-12, 2020 (Press release, Centene , FEB 21, 2020, View Source [SID1234554620]).

Centene will present on Tuesday, March 10, at 8:00 a.m. Eastern Daylight Time (EDT). A simultaneous live audio webcast is available at: View Source;tp_key=5ec58b2d8f.

A webcast replay of this presentation will be available afterwards via the Company’s website at www.centene.com under the Investors section.

Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2019 Results Presentation and Webcast

On February 21, 2020 Nordic Nanovector ASA (OSE: NANO) reported that it will report its results for the fourth quarter and full year 2019 on Thursday, 27 February 2020 (Press release, Nordic Nanovector, FEB 21, 2020, View Source [SID1234554619]). A presentation by Nordic Nanovector’s senior management team will take place at 8:30am CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: VIPPETANGEN

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2019 from 7:00am CET the same day.

Quanterix Corporation to Release Fourth Quarter 2019 Financial Results on March 9, 2020 and Present at Multiple Upcoming Healthcare Conferences

On February 21, 2020 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, reported that it will release its financial results for fourth quarter 2019 after the close of trading on Monday, March 9, 2020 (Press release, Quanterix, FEB 21, 2020, View Source [SID1234554618]). Company management will host a conference call at 4:30 p.m., EST to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chief Executive Officer, President and Chairman, Quanterix.

Individuals interested in listening to the conference call may do so by dialing (833) 686-9351 for domestic callers, or (612) 979-9890 for international callers. Please reference the following conference ID: 8171579. A live webcast will also be available at: View Source The webcast will be available on the Company’s website, View Source, for one year following completion of the call.

Additionally, Quanterix announced the company will be presenting and hosting one-on-one meetings with investors at multiple high-profile healthcare conferences. Hrusovsky will present at the Ninth Annual Leerink Partners Global Healthcare Conference on Wednesday, February 26, 2020 at 3:30 p.m., EST at the Lotte New York Palace in New York City, NY. He will also present at the 40th Annual Cowen and Company Health Care Conference, on Tuesday, March 3, 2020 at 10:40 a.m., EST at the Marriott Copley in Boston, Massachusetts. This presentation will be followed by a Q&A session at 11:20 a.m., EST.

To access the live webcast of Quanterix’ presentations, please visit the News & Events page within the Investors section of the Quanterix website at View Source. Replays of the webcasts will be available on the Quanterix website for 90 days following the conference.

Genetron Health and InnoCare Team Up In Partnership To Accelerate the Development and Commercialization of Novel Drugs for Cancer Treatment

On February 21, 2020 Genetron Holding Limited ("Genetron Health"), a China-based precision oncology company that covers full-cycle cancer care, has reported a strategic partnership with Beijing InnoCare Pharma Tech Co., Ltd. ("InnoCare") to provide clinical trial genomic testing and companion diagnostics development services for InnoCare’s biomarker-driven oncology drug development (Press release, Genetron Health Technologies, FEB 21, 2020, View Source [SID1234554617]).

Committed to advancing the research and development process and clinical utility of biopharmaceutical companies’ novel biomarker-driven oncology drug, Genetron Health has already formed partnerships with dozens of leading companies including AstraZeneca, Roche, Novartis, CStone Pharmaceuticals, Alphamab, Juventus Cell Therapy, EdiGene, etc.

Benchmarking global quality standards, Genetron Health has built a one-stop comprehensive genomic profiling platform to support drug research and development for multinational and local innovative biopharmaceutical companies and biomedical CRO partners. Genetron Health provides a range of services, including biomarker evaluation for molecularly targeted therapy and immuno-therapy, clinical trial enrolment and testing, companion diagnostics development and commercialization and joint-marketing post-drug approval.

Clinical trial enrollment and testing: Genetron Health provides a seamless, integratedsolution covering clinical trial consulting and planning, GCP-complied molecular and immuno testing services based on its CAP and CLIA certificated laboratories, patient recruitment and enrollment, and data collection and analysis.
Companion diagnostics development and commercialization: Genetron Health has a comprehensive NMPA-approved technology platform covering NGS, dPCR and qPCR for companion diagnostics development, a professional and experienced team for IVD product registration and innovative patented technologies such as the One-Step Seq Method. As a pioneer in the field of precision oncology in China, Genetron Health can provide customized and integrated diagnostic assay development and commercialization services to meet the needs of biopharmaceutical companies. For instance, in December 2019, Genetron health announced strategic partnership with CStone Pharmaceuticals on companion diagnostics and clinical trial testing.
Early-stage R&D and real world study (RWS): Genetron Health has a large real-world cancer genomics database and proven research capabilities and technologies to provide powerful genomic testing services and data research support for early-stage R&D, biomarker development and RWS needs of biopharmaceutical companies, CROs, and research institutions.